| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional … B Ricciuti, C Genova, A De Giglio, M Bassanelli, MG Dal Bello, G Metro, ... Journal of cancer research and clinical oncology 145, 479-485, 2019 | 290 | 2019 |
| Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine G Metro, J Foglietta, M Russillo, L Stocchi, A Vidiri, D Giannarelli, L Crinò, ... Annals of oncology 22 (3), 625-630, 2011 | 195 | 2011 |
| Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy B Ricciuti, C Mencaroni, L Paglialunga, F Paciullo, L Crino, R Chiari, ... Medical oncology 33, 1-12, 2016 | 165 | 2016 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 136 | 2019 |
| Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ... Journal of Experimental & Clinical Cancer Research 30, 1-7, 2011 | 134 | 2011 |
| Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib F Cappuzzo, L Toschi, G Tallini, GL Ceresoli, I Domenichini, S Bartolini, ... Annals of oncology 17 (7), 1120-1127, 2006 | 134 | 2006 |
| HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care A Fabi, A Di Benedetto, G Metro, L Perracchio, C Nisticò, F Di Filippo, ... Clinical Cancer Research 17 (7), 2055-2064, 2011 | 129 | 2011 |
| CSF concentration of crizotinib in two ALK-positive non–small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment G Metro, G Lunardi, P Floridi, JP Pascali, L Marcomigni, R Chiari, ... Journal of Thoracic Oncology 10 (5), e26-e27, 2015 | 110 | 2015 |
| Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and … A Addeo, GL Banna, G Metro, M Di Maio Frontiers in oncology 9, 264, 2019 | 96 | 2019 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 94 | 2021 |
| Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype G Metro, R Chiari, S Duranti, A Siggillino, MJ Fischer, D Giannarelli, ... Lung cancer 78 (1), 81-86, 2012 | 92 | 2012 |
| Future options for ALK-positive non-small cell lung cancer D Iacono, R Chiari, G Metro, C Bennati, G Bellezza, M Cenci, B Ricciuti, ... Lung cancer 87 (3), 211-219, 2015 | 77 | 2015 |
| Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications B Ricciuti, GC Leonardi, G Metro, F Grignani, L Paglialunga, G Bellezza, ... Expert Review of Respiratory Medicine 10 (1), 53-68, 2016 | 74 | 2016 |
| Advances on EGFR mutation for lung cancer G Metro, L Crinò Translational lung cancer research 1 (1), 5, 2012 | 70 | 2012 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC) G Metro, G Finocchiaro, L Toschi, S Bartolini, E Magrini, A Cancellieri, ... Reviews on recent clinical trials 1 (1), 1-13, 2006 | 68 | 2006 |
| Therapeutic options targeting angiogenesis in nonsmall cell lung cancer L Crinò, G Metro European respiratory review 23 (131), 79-91, 2014 | 67 | 2014 |
| Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity A Inno, G Metro, P Bironzo, AM Grimaldi, E Grego, V Di Nunno, V Picasso, ... Tumori Journal 103 (5), 405-421, 2017 | 66 | 2017 |
| Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence B Ricciuti, M Brambilla, G Metro, S Baglivo, R Matocci, M Pirro, R Chiari Medical oncology 34, 1-8, 2017 | 66 | 2017 |
| Clinical experience with gefitinib: an update F Cappuzzo, G Finocchiaro, G Metro, S Bartolini, E Magrini, A Cancellieri, ... Critical reviews in oncology/hematology 58 (1), 31-45, 2006 | 64 | 2006 |
